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In 1989–96, men with prostate cancer who
participated in a treatment trial were randomized
to either radical prostatectomy or watchful wait-
ing; in 1997–98, 1–8 years after randomization, the
effect of follow-up period, physical symptoms, and
androgen deprivation on health-related quality of
life (QoL) was assessed [1]. Randomized treatment
trials in men with prostate cancer are very scarce.
Because of randomization, no big differences are
expected at baseline between the treatment
groups; however, not all initially randomized
men were still alive when QoL was assessed, and
survival and response rates were not necessarily
identical in both groups. As a result, essential
information on the magnitude of differences that
may exist between the groups is lacking in this
paper.
Stratified for the number of physical symptoms,
the radical prostatectomy group appeared to have a
better QoL and less anxiety and depression than
the watchful waiting group [1]. Remarkably, results
suggest a bigger negative impact from becoming
impotent due to hormonal treatment than from
becoming impotent due to surgery. Maybe this
finding is so because the latter treatment had a
curative intention? But in that case, men treated by
surgery may have been more disappointed—and
depressed—when they appeared not to be cured.
My main objection to this paper is that results
are presented as if men were followed through the
years, whereas each man completed an assess-
ment only once. To establish causal relationships
between treatment and effects on QoL, longitudi-
nal, prospective research is needed, preferably
including pretreatment assessments. The ongoing
PROTECT trial on prostate cancer screening and
treatment may provide such data in the coming
years [2].
In the current study, 88% of men had clinically
detected tumors [1]. Nowadays, the majority of
patients are identified through prostate-specific
antigen (PSA) testing, which advances diagnosis
with some 11 yr [3]. Men who are currently
diagnosed with prostate cancer and treated by
watchful waiting (or, rather, ‘‘active surveillance’’)
may expect a much longer period without symp-
toms and without androgen deprivation than the
men in this study.
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